Mostrando postagens com marcador Liver diseases. Mostrar todas as postagens
Mostrando postagens com marcador Liver diseases. Mostrar todas as postagens

sábado, 29 de novembro de 2014

Leading medical experts call for an end to UK postcode lottery for liver disease treatment, detection

 


In a major new Lancet Commission, led by Professor Roger Williams, Director of the Institute of Hepatology, London, UK, doctors and medical scientists from across the UK call for a radical scale up of liver disease treatment and detection facilities in the country, which has one of the worst rates of death from liver disease in Europe.

The UK is the only country in western Europe (except Finland) where the prevalence of liver disease has increased in the past three decades, and the rate of death from the disease for those under the age of 65 years has increased by almost 500% since 1970.

"There is a human, social, and financial imperative to act now if the UK's burden of liver disease and all its consequences are to be tackled and the NHS is not to be overwhelmed by the cost of treating advanced stage liver disease," says Professor Williams.

Although 1 in 10 people in the UK will experience liver disease at some stage in their lifetime, the Commission shows that nationally, early detection of liver disease through primary care services (such as GPs and walk-in centres) is virtually non-existent, despite the fact that the disease is much more effectively treated when identified early.

As a recent Public Health England (PHE) report showed, the burden of liver disease in different regions of the UK is closely linked to socioeconomic deprivation, with areas such as the north west of England experiencing nearly four times as many deaths from liver disease as more affluent areas.

Despite the fact that these regions experience a far greater burden of death and illness from liver disease, the Commission shows that specialist treatment services for liver disease in its advanced stages are unevenly distributed throughout the UK, with some of the regions most badly affected having inadequate specialist provision, leading to a postcode lottery for patients which is resulting in unacceptable rates of death and illness in many regions of the UK.

As well as improving treatment and detection services, the Commission demonstrates that a powerful commitment is needed from UK policymakers to implement policies which address the lifestyle factors leading to most death and illness from liver disease, especially excessive alcohol use and obesity. This includes recommendations to implement minimum pricing policies for alcohol, prominent health warnings on alcohol packaging, and regulation of sugar content in food and soft drinks.

The Commission provides a cost-effective and achievable blueprint for improving hospital care for people with severe liver disease, by recommending that Liver Units providing acute services are established in every District General Hospital in the UK, linked with 30 Specialist Centres -- for more complicated cases -- distributed equitably around the country. Screening of high risk individuals using new diagnostic techniques are part of proposed improvements at GP and community level.The authors also recommend a review of the transplant services to ensure better access for patients in some areas of the country, and to ensure sufficient capacity for an anticipated 50% increase in availability of donor organs by 2020.

Although the report highlights shortcomings of the current national provision for liver disease in adults, it shows that UK services for childhood liver disease -including genetic disorders or viral infection -- could, in terms of their centralised funding and organisation, provide a positive example for improving adult services.

The report also suggests that another major cause of liver disease, hepatitis C, could be eliminated from the UK by 2030, now that safe and highly effective antiviral drugs are available. The spread of hepatitis B also needs to be controlled, with monitoring of immigrants from countries with high prevalence of the infection bringing new infections into the country a priority.

According to Professor Williams, "This Commission builds on recent work by the All Party Parliamentary Group on Hepatology and Public Health England, amongst others, to clearly identify the scale of the problem posed by liver disease in the UK, and current deficiencies in NHS care provision. The evidence outlined in the report, contributed by some of the UK's leading experts in the field, should leave nobody in any doubt about the present unacceptable levels of premature death and the overall poor standards of care being afforded to liver patients."

"The good news is that if our recommendations -- many of which will require additional government regulatory action -- are followed, deaths from liver disease will fall, with profound benefits in health and social wellbeing and economic productivity, as well as reduced costs for the NHS. However, the health and policy reforms we are recommending need to take place now -- the scale of the problem is too great for it to take second place to short-term political considerations."


Story Source:

The above story is based on materials provided by The Lancet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Roger Williams, Richard Aspinall, Mark Bellis, Ginette Camps-Walsh, Matthew Cramp, Anil Dhawan, James Ferguson, Dan Forton, Graham Foster, Sir Ian Gilmore, Matthew Hickman, Mark Hudson, Deirdre Kelly, Andrew Langford, Martin Lombard, Louise Longworth, Natasha Martin, Kieran Moriarty, Philip Newsome, John O'Grady, Rachel Pryke, Harry Rutter, Stephen Ryder, Nick Sheron, Tom Smith. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. The Lancet, 2014; DOI: 10.1016/S0140-6736(14)61838-9

 

segunda-feira, 24 de novembro de 2014

Update on new treatments for liver diseases

 


Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases.

Promising Probiotic for Liver Disease

A study published in Gastroenterology found that, over a six-month period, daily intake of the probiotic VSL#3® significantly improved liver function and reduced the risk of hospitalization in patients with cirrhosis. Patients who received the probiotic also had a reduction in the development of hepatic encephalopathy, the worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. There were no adverse events related to VSL#3.

The authors have no conflicts to disclose.

Drug Reduces Liver Fat Content in NAFLD Patients

Publishing in Clinical Gastroenterology and Hepatology, researchers report that three months' administration of the fatty acid/bile acid conjugate Aramchol is safe, tolerable and significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol is a candidate for the treatment of fatty liver-related diseases, currently an unmet need.

This research was supported by Galmed Medical Research, Ltd.

Resveratrol Does Not Benefit Patients with NAFLD

Reporting in Clinical Gastroenterology and Hepatology, researchers find that eight weeks administration of resveratrol did not induce therapeutic benefits in men with established NAFLD, compared with placebo. Caution is warranted for use in obesity with chronic liver disease until further research determines safety.

This research was supported by the Princess Alexandra Research Foundation, the Lions Medical Research Foundation, and the National Health and Medical Research Council of Australia.


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Journal References:

  1. Radha K. Dhiman, Baldev Rana, Swastik Agrawal, Ashish Garg, Madhu Chopra, Kiran K. Thumburu, Amit Khattri, Samir Malhotra, Ajay Duseja, Yogesh K. Chawla. Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial. Gastroenterology, 2014; 147 (6): 1327 DOI: 10.1053/j.gastro.2014.08.031
  2. Rifaat Safadi, Fred M. Konikoff, Mahmud Mahamid, Shira Zelber-Sagi, Maya Halpern, Tuvia Gilat, Ran Oren. The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014; 12 (12): 2085 DOI: 10.1016/j.cgh.2014.04.038
  3. Rifaat Safadi, Fred M. Konikoff, Mahmud Mahamid, Shira Zelber-Sagi, Maya Halpern, Tuvia Gilat, Ran Oren. The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014; 12 (12): 2085 DOI: 10.1016/j.cgh.2014.04.038

:

quinta-feira, 16 de outubro de 2014

Immune cells in liver drive fatty liver disease, liver cancer

 

October 14, 2014

Helmholtz Zentrum München - German Research Center for Environmental Health

Immune cells that migrate to the liver and interact there with liver tissue cells get activated by metabolic stress (e.g. through lipids of a high fat diet) and drive the development of fatty liver disease, non-alcoholic steatohepatitis and liver cancer. Scientists made this discovery and thus identified the previously unknown mechanism underlying these serious and widespread diseases.


Human hepatozytes filled with lipids representing macro-vesicular steatosis in hepatocytes (arrows) and inflamed cells (arrow head) caused by chronic fat diet.

Fatty liver disease -- alongside fatty liver due to massive alcohol consumption -- is mainly caused by excessive consumption of fat and sugar combined with a lack of exercise or a sedentary life style. This is referred to as non-alcoholic fatty liver disease (NAFLD). If NAFLD becomes chronic -- e.g. through the constant uptake of high lipids and high sugar combined with lack of excercise a chronic inflammatory response is triggered in the liver tissue in addition. This can lead to non-alcoholic steatohepatitis (NASH) -- a liver disease with clear detectable pathologic alteratons of the tissue.

These liver diseases (NAFLD and NASH), along with chronic viral infections, are the most common causes of liver cancer, or hepatocellular carcinoma (HCC). In the United States, about 90 million people suffer from NAFLD. In Europe, the figure is more than 40 million, and even in threshold countries like India and China, the number of people affected is rising due to increasingly unhealthy lifestyles. More worrying, in all of the above mentioned states the numbers of NAFLD and NASH patients is constantly increasing. Consequently, the incidence of HCC resulting from NASH and NAFLD is also rising worldwide. In the United States, HCC is the fastest-growing form of cancer at the moment. No efficient causal therapy exists for HCC patients of which approximately 800,000 die every year.

T cells involved in the development of fatty liver disease, NASH and HCC

The mechanisms that cause diseases such as fatty liver disease, steatohepatitis and HCC are still not widely understood. However, immune cells, particularly CD8+ T cells and NK T cells seem to play an important role. This finding was made by a team of scientists led by Prof. Mathias Heikenwälder, Prof. Matthias Tschöp, Dr. Kerstin Stemmer, Dr. Kristian Unger, Prof. Ulrike Protzer and the working group of Dr. Hans Zischka from the Helmholtz Zentrum München together with a team headed by Prof. Percy Knolle of the Technische Universität München (TUM), Prof. Achim Weber from Zurich University Hospital and Dr. Monika Wolf, Institute of Surgical Pathology, University Hospital Zurich. The animal model which was used to examine the long-term effects of metabolic syndrome* enabled the scientists to elucidate new mechanisms that cause fatty liver disease and also show how it can develop into liver cancer.

Inflammatory events offer starting point for prevention and treatment

The scientists assume that an existing metabolic imbalance results in the activation and migration of immune cells to the liver. There, the immune cells interact with liver cells and trigger an inflammatory response that damages the liver tissue and also destabilizes the metabolic activity of the liver cells. "Initially it immune cells promote fatty liver degeneration. The inflammation, which is triggered by specific immune cells, encourages the progression of fatty liver pathology and causes NASH to develop. These processes are the basis for liver cell degeneration, which can cause HCC," explains Prof. Heikenwälder, who led the study. "Our results provide completely new insights into the development of these serious liver diseases. Building on this knowledge, we now want to develop new, preventive and therapeutic strategies to combat these diseases." The initial studies are already under way in the preclinical model.

*Metabolic syndrome: a combination of obesity / abdominal adiposity, insulin resistance, raise levels of lipids in the blood and raised blood pressure.


Story Source:

The above story is based on materials provided by Helmholtz Zentrum München - German Research Center for Environmental Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. Monika Julia Wolf, Arlind Adili, Kira Piotrowitz, Zeinab Abdullah, Yannick Boege, Kerstin Stemmer, Marc Ringelhan, Nicole Simonavicius, Michèle Egger, Dirk Wohlleber, Anna Lorentzen, Claudia Einer, Sabine Schulz, Thomas Clavel, Ulrike Protzer, Christoph Thiele, Hans Zischka, Holger Moch, Matthias Tschöp, Alexei V. Tumanov, Dirk Haller, Kristian Unger, Michael Karin, Manfred Kopf, Percy Knolle, Achim Weber, Mathias Heikenwalder. Metabolic Activation of Intrahepatic CD8 T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes. Cancer Cell, 2014; 26 (4): 549 DOI: 10.1016/j.ccell.2014.09.003

 
 

Helmholtz Zentrum München - German Research Center for Environmental Health. "Immune cells in liver drive fatty liver disease, liver cancer." ScienceDaily. ScienceDaily, 14 October 2014. <www.sciencedaily.com/releases/2014/10/141014152536.htm>.

segunda-feira, 22 de setembro de 2014

Artificial liver tested as potential therapy for patients with alcohol-related organ failure

 

September 22, 2014

Cedars-Sinai Medical Center

A novel, human cell based, bioartificial liver support system is being tested for patients with acute liver failure, often a fatal diagnosis. The external organ support system is designed to perform critical functions of a normal liver, including protein synthesis and the processing and cleaning of a patient's blood. The filtered and treated blood is then returned to the patient through the central line.


ELAD® investigational bio-artificial liver support system.

Cedars-Sinai physicians and scientists are testing a novel, human cell based, bioartificial liver support system for patients with acute liver failure, often a fatal diagnosis.

"The quest for a device that can fill in for the function of the liver, at least temporarily, has been underway for decades. A bioartificial liver, also known as a BAL, could potentially sustain patients with acute liver failure until their own livers self-repair," said Steven D. Colquhoun, MD, the surgical director of liver transplantation at Cedars-Sinai's Comprehensive Transplant Center.

Colquhoun is leading an investigation at Cedars-Sinai to assess the safety and effectiveness of the ELAD® bioartificial liver system, which is designed by Vital Therapies Inc., the sponsor of the clinical trials. The majority of the 49 sites currently involved in the investigation are in the United States, but studies are also underway in Europe and Australia. The research at Cedars-Sinai involves patients with liver disease caused by acute alcoholic hepatitis, a group with few therapeutic options.

In the bioartificial liver under investigation, blood is drawn from the patient via a central venous line, and then is filtered through a component system featuring four tubes, each about 1 foot long, which are embedded with liver cells. The external organ support system is designed to perform critical functions of a normal liver, including protein synthesis and the processing and cleaning of a patient's blood. The filtered and treated blood is then returned to the patient through the central line.

"If successful, a bioartificial liver could not only allow time for a patient's own damaged organ to regenerate, but also promote that regeneration. In the case of chronic liver failure, it also potentially could support some patients through the long wait for a liver transplant," said Colquhoun.

The functions of the liver are very complex. The 3-pound organ that sits to the right of the stomach performs many functions including detoxification, regulation of glucose levels and the making of vital proteins. Liver failure can be caused by trauma, such as an accident, by viral infections, overdosing on drugs -- including some over-the-counter pain medications -- and from alcohol abuse. Liver failure is often life-threatening in a matter of days.

Devices that do the work of human organs have been used successfully for years. Patients with kidney disease can use dialysis, and those with cardiac problems have ventricular assist devices or artificial hearts available to support or replace vital organ functions.

"Liver failure patients and their doctors have long been frustrated by the critical need to provide the kind of life-saving care kidney patients are afforded by dialysis. This important investigation we are undertaking at Cedars-Sinai is a critical step in addressing the medical emergency presented by liver failure," said Andrew S. Klein MD, MBA, director of the Comprehensive Transplant Center and the Esther and Mark Schulman Chair in Surgery and Transplantation Medicine.


Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.


Cite This Page: